Absci Corp (ABSI)

Currency in USD
3.000
+0.050(+1.69%)
Closed·
2.9800.000(0.00%)
·
ABSI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.8703.040
52 wk Range
2.2405.228
Key Statistics
Prev. Close
2.95
Open
2.96
Day's Range
2.87-3.04
52 wk Range
2.24-5.228
Volume
3.59M
Average Volume (3m)
3.55M
1-Year Change
22.1996%
Book Value / Share
1.26
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ABSI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.029
Upside
+167.62%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Absci Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Absci Corp Earnings Call Summary for Q4/2025

  • Q4 2025 EPS of -$0.20 missed forecast of -$0.18 by 11%; revenue of $700K fell 49% short of $1.38M estimate, triggering 1.54% stock decline.
  • R&D expenses surged 37.5% YoY to $25.3M, reflecting increased investment in clinical pipeline, particularly ABS-201 program development.
  • Company maintains strong cash position of $144.3M as of Dec 31, 2025, projected to fund operations through 2028 despite revenue shortfall.
  • Forward guidance remains cautious with EPS forecast at -$0.18 for upcoming quarters; executives emphasize ABS-201 clinical trial progress as growth driver.
  • Stock trading at $2.885 near 52-week low with beta of 2.13, indicating high volatility; InvestingPro suggests potential overvaluation concerns.
Last Updated: 03/25/2026, 05:50 AM
Read Full Transcript

Compare ABSI to Peers and Sector

Metrics to compare
ABSI
Peers
Sector
Relationship
P/E Ratio
−4.0x−4.5x−0.4x
PEG Ratio
−0.39−0.180.00
Price/Book
2.4x4.8x2.6x
Price / LTM Sales
164.8x23.6x3.2x
Upside (Analyst Target)
205.1%72.1%50.6%
Fair Value Upside
Unlock7.4%6.6%Unlock

Analyst Ratings

8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 8.029
(+167.62% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Morgan Stanley
Hold4.20+40.00%4.32MaintainMar 25, 2026
Morgan Stanley
Hold4.32+44.00%5.80DowngradeJan 08, 2026
H.C. Wainwright
Buy8.00+166.67%7.00MaintainDec 17, 2025
Jones Trading
Buy9.00+200.00%8.00MaintainNov 28, 2025
Morgan Stanley
Buy5.80+93.33%5.89MaintainNov 17, 2025

Earnings

Latest Release
Mar 24, 2026
EPS / Forecast
-0.20 / -0.18
Revenue / Forecast
700K / 1.38M
EPS Revisions
Last 90 days

ABSI Income Statement

People Also Watch

9.130
ONDS
-0.11%
37.54
FLY
-0.08%
12.370
RCAT
+3.69%
9.280
RDW
+0.65%

FAQ

What Is the Absci (ABSI) Stock Price Today?

The Absci stock price today is 3.000 USD.

What Stock Exchange Does Absci Trade On?

Absci is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Absci?

The stock symbol for Absci is "ABSI."

What Is the Absci Market Cap?

As of today, Absci market cap is 454.470M USD.

What Is Absci's Earnings Per Share (TTM)?

The Absci EPS (TTM) is -0.842.

When Is the Next Absci Earnings Date?

Absci will release its next earnings report on May 19, 2026.

From a Technical Analysis Perspective, Is ABSI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Absci Stock Split?

Absci has split 0 times.

How Many Employees Does Absci Have?

Absci has 140 employees.

What is the current trading status of Absci (ABSI)?

As of Apr 10, 2026, Absci (ABSI) is trading at a price of 3.000 USD, with a previous close of 2.950 USD. The stock has fluctuated within a day range of 2.870 USD to 3.040 USD, while its 52-week range spans from 2.240 USD to 5.228 USD.

What Is Absci (ABSI) Price Target According to Analysts?

The average 12-month price target for Absci is 8.029 USD, with a high estimate of 10 USD and a low estimate of 4.2 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +167.62% Upside potential.

What Is the ABSI Premarket Price?

ABSI's last pre-market stock price is 2.999 USD. The pre-market share volume is 23,250.000, and the stock has decreased by 0.049, or 1.660%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.